DOYLESTOWN, Pa.–(BUSINESS WIRE)–Diverse Biotech, Inc., https://diversebiotech.com, announced today that its DBT-12733 molecule was more effective in killing glioblastoma tumor cells than temozolomide (Temodar®), outperforming all expectations in early testing. In fact, DBT-12733 maintained its efficacy against the temozolomide-resistant glioblastoma cancer cell line T98G, with an 8,000-fold higher effect.

“T98G cells are actually resistant to temozolomide, due to a cellular change that results in limited treatment options for patients. DBT-12733 has shown to be most effective at killing cells with this particular alteration.”

Tweet this

• 25 times (25x) more effective on A172 cells
• 50 times (50x) more effective on U87-MG cells
• 8,000 times (8,000x) more effective on T98G cells

Chief Science Officer, Philip Arlen, PhD, adds, “T98G cells are actually resistant to temozolomide, due to a cellular change that results in limited treatment options for patients. DBT-12733 has shown to be most effective at killing cells with this particular alteration.”

Glioblastoma is very hard to treat. On May 4^th, 2020, the FDA granted Diverse Biotech “Orphan Drug Status” for this investigational drug for the treatment of glioblastoma, and it continues to show significant promise against the disease.

Board Chairman William Fisher said, “I was pleasantly surprised with the results against T98G cells. We are increasingly having a better idea of the capabilities of what’s coming through our pipeline and the data is extraordinary. We are excited to get this new molecule over to our collaborators at The Preston Robert Tisch Brain Tumor Center at Duke University for further studies.”

About Diverse Biotech
Diverse Biotech is focused primarily on drug-discovery and biopharmaceutical research. Diverse is committed to discovering and developing novel therapies from its patented novel drug platform. Diverse has succeeded in improving the cannabinoid molecule by creating a novel new class of cancer fighting drugs, never-before existing in nature.

In addition to licensing of intellectual property to other drug companies, the vast unmet need for treatment in specific major-disease categories, implores Diverse take a number of our novel drugs to market.

One segment of the Diverse drug pipeline are molecules that have shown significantly higher effectiveness and less toxicity than chemotherapy. They utilize the cannabinoid molecule “frame” creating a new molecule that is part-chemotherapy, part-cannabinoid.

Diverse patents create a new class of drugs, generating literally thousands of these new molecules available for licensing to multiple pharmaceutical companies in all disease categories.

Further information about Diverse Biotech can be found at https://diversebiotech.com.